March 26, 2008

Encision Launches Next Generation of EnTouch® Handles for Advanced Laparoscopic Procedures

Boulder, Colorado, March 26, 2008 – Encision Inc. (AMEX:ECI) ("Encision" or the "Company") announced today that it is launching its next generation of EnTouch handles for its AEM® articulating laparoscopic instrument inserts.

The new ES8200 and ES8200L handles feature a stiffer shaft design to accommodate the stresses generated by organ manipulation during advanced as well as routine laparoscopic procedures. In addition, the new, easy to operate rotation knob design allows a surgeon to lock the electrode tip in the preferred orientation for the particular need during a laparoscopic procedure. The EnTouch model ES8200 is 35cm in length for normal size patients while the ES8200L is 45cm in length for large patients and many bariatric procedures.

"Our goal is to offer the ultimate in patient safety along with best of class ergonomic instruments for the surgeon performing laparoscopy," said Jack Serino, Encision President & CEO. Handle sales represented approximately 10% of the Company's revenue for its fiscal year ended March 31, 2007.

Encision Inc. designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, insufficient quantity of new account conversions, insufficient cash to fund operations, scale up production to meet delivery obligations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission.

CONTACT: Marcia McHaffie, Encision Inc., 303-444-2600, mmchaffie@encision.com